Stock Research for ALPMY

ALPMY

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ALPMY Stock Chart & Research Data

The ALPMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ALPMY Due diligence Resources & Stock Charts

The ALPMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALPMY Detailed Price Forecast - CNN Money CNN View ALPMY Detailed Summary - Google Finance
Yahoo View ALPMY Detailed Summary - Yahoo! Finance Zacks View ALPMY Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ALPMY Trends & Analysis - Trade-Ideas Barrons View ALPMY Major Holders - Barrons
NASDAQ View ALPMY Call Transcripts - NASDAQ Seeking View ALPMY Breaking News & Analysis - Seeking Alpha
Spotlight View ALPMY Annual Report - CompanySpotlight.com OTC Report View ALPMY OTC Short Report - OTCShortReport.com
TradeKing View ALPMY Fundamentals - TradeKing Charts View ALPMY SEC Filings - Bar Chart
WSJ View Historical Prices for ALPMY - The WSJ Morningstar View Performance/Total Return for ALPMY - Morningstar
MarketWatch View the Analyst Estimates for ALPMY - MarketWatch CNBC View the Earnings History for ALPMY - CNBC
StockMarketWatch View the ALPMY Earnings - StockMarketWatch MacroAxis View ALPMY Buy or Sell Recommendations - MacroAxis
Bullish View the ALPMY Bullish Patterns - American Bulls Short Pains View ALPMY Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ALPMY Stock Mentions - StockTwits PennyStocks View ALPMY Stock Mentions - PennyStockTweets
Twitter View ALPMY Stock Mentions - Twitter Invest Hub View ALPMY Investment Forum News - Investor Hub
Yahoo View ALPMY Stock Mentions - Yahoo! Message Board Seeking Alpha View ALPMY Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ALPMY - SECform4.com Insider Cow View Insider Transactions for ALPMY - Insider Cow
CNBC View ALPMY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALPMY - OTC Markets
Yahoo View Insider Transactions for ALPMY - Yahoo! Finance NASDAQ View Institutional Holdings for ALPMY - NASDAQ


Stock Charts

FinViz View ALPMY Stock Insight & Charts - FinViz.com StockCharts View ALPMY Investment Charts - StockCharts.com
BarChart View ALPMY Stock Overview & Charts - BarChart Trading View View ALPMY User Generated Charts - Trading View


Latest Financial News for ALPMY

Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
Posted on Sunday June 03, 2018

-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study- TOKYO and BOTHELL, Wash. , June 3, 2018 /PRNewswire/ --   ...


Astellas Oncology C3 Prize® Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World
Posted on Thursday May 31, 2018

TOKYO, May 31, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the launch of the third annual Astellas Oncology C3 Prize (Changing Cancer Care), a global challenge aimed at inspiring non-treatment ideas that may improve cancer care for patients and their loved ones.


How Is Merck’s Hospital Acute Care Segment Positioned?
Posted on Wednesday May 30, 2018

Merck & Company’s (MRK) Bridion generated revenue of $204 million in Q1 2018 compared to $148 million in Q1 2017, which reflected a ~38% rise YoY (year-over-year) and a 2% fall sequentially.


U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Posted on Tuesday May 29, 2018

TOKYO , May 29, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has ...


Enter a stock symbol to view the stock details.